Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $58.00 at JPMorgan Chase & Co.
Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price target raised by JPMorgan Chase & Co. from $55.00 to $58.00 in a report published on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the biopharmaceutical company’s stock. HALO has been the topic of several other reports. Benchmark reiterated a “buy” […]
Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price target raised by JPMorgan Chase & Co. from $55.00 to $58.00 in a report published on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the biopharmaceutical company’s stock. HALO has been the topic of several other reports. Benchmark reiterated a “buy” […]
